מזומנים למניה אחת Amicus Corp (FOLD)

The scientific potential of Amicus Therapeutics (FOLD) is based on cutting-edge developments in gene therapy and protein chaperones. This is supported by a broad portfolio of drugs for rare pathologies successfully marketed in Europe and the US. Leadership in the enzyme replacement therapy niche provides the company with a global advantage. The cash per share on this chart confirms liquidity, and 0.93 expresses the value of the metric today.
פילוחי מדדים מקיפים ואנליטיקה עבור Amicus Therapeutics Inc (FOLD)

Selecting high-quality issuers requires a liquidity analysis via the ratio of net cash to the number of shares, which determines the business's margin of safety in the event of a revenue decline. For Amicus Therapeutics (FOLD), which has transitioned to drug commercialization without M&A activity, the trend of the cash cushion per share reflects the burn rate of reserves for the sales launch, allowing for an assessment of the company's autonomy without external borrowing.